甘油三酯与心血管结局——我们能降低它吗？
Triglycerides and Cardiovascular Outcomes-Can We REDUCE-IT ?
作者信息
Pradhan Akshyaya, Bhandari Monika, Vishwakarma Pravesh, Sethi Rishi
机构信息
Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India.
出版信息
Int J Angiol. 2020 Mar;29(1):2-11. doi: 10.1055/s-0040-1701639. Epub 2020 Feb 25.
Abstract
The causal linkage between triglycerides and coronary artery disease has been controversial. Most of the trials hitherto have shown marginal or no beneficial effects of reduction of triglycerides (with fibrates) on top of low-density lipoprotein (LDL) reduction. But a significant residual cardiovascular risk remains even after use of high dose of statins. Omega-3 fatty acids have been shown to reduce triglyceride levels and some old trials have shown the benefits of fish oils in reducing cardiovascular events. However, barring a few trials most of the large trials of omega-3 fatty acids are negative. Recently, few large trials have been conducted to see the effects of high dose omega-3 fatty acids on cardiovascular outcomes and some of them have shown promising results on top of LDL reduction.
摘要
甘油三酯与冠状动脉疾病之间的因果联系一直存在争议。迄今为止，大多数试验表明，在降低低密度脂蛋白（LDL）的基础上，降低甘油三酯（使用贝特类药物）的益处甚微或没有益处。但即使使用高剂量他汀类药物后，仍存在显著的残余心血管风险。ω-3脂肪酸已被证明可降低甘油三酯水平，一些早期试验表明鱼油在降低心血管事件方面有益处。然而，除了少数试验外，大多数关于ω-3脂肪酸的大型试验结果都是阴性的。最近，已经进行了一些大型试验来观察高剂量ω-3脂肪酸对心血管结局的影响，其中一些试验在降低LDL的基础上显示出了有希望的结果。
相似文献
1
Triglycerides and Cardiovascular Outcomes-Can We REDUCE-IT ?甘油三酯与心血管结局——我们能降低它吗？
Int J Angiol. 2020 Mar;29(1):2-11. doi: 10.1055/s-0040-1701639. Epub 2020 Feb 25.
2
TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.甘油三酯、动脉粥样硬化与心血管结局研究：聚焦于ω-3脂肪酸
Endocr Pract. 2017 Jan;23(1):100-112. doi: 10.4158/EP161445.RA. Epub 2016 Nov 7.
3
Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.长链ω-3脂肪酸、贝特类药物和烟酸作为高甘油三酯血症治疗的治疗选择：文献综述
Atherosclerosis. 2015 Oct;242(2):647-56. doi: 10.1016/j.atherosclerosis.2015.06.012. Epub 2015 Jun 11.
4
Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.二十碳五烯酸与二十二碳六烯酸作为预防血管风险的选择：一个与鱼有关的故事
Am J Ther. 2016 May-Jun;23(3):e905-10. doi: 10.1097/MJT.0000000000000165.
5
Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.在管理式医疗环境中，以低高密度脂蛋白胆固醇为靶点降低残余心血管风险。
J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1.
6
Optimal management of combined dyslipidemia: what have we behind statins monotherapy?混合性血脂异常的优化管理：他汀类药物单一疗法之后我们还有什么？
Adv Cardiol. 2008;45:127-153. doi: 10.1159/000115192.
7
Comparative cardiometabolic effects of fibrates and omega-3 fatty acids.贝特类药物与 ω-3 脂肪酸的心脏代谢比较效应。
Int J Cardiol. 2013 Sep 10;167(6):2404-11. doi: 10.1016/j.ijcard.2013.01.223. Epub 2013 Feb 27.
8
Omacor and omega-3 fatty acids for treatment of coronary artery disease and the pleiotropic effects.奥米加-3脂肪酸乙酯（Omacor）与ω-3脂肪酸用于治疗冠状动脉疾病及多效性作用
Am J Ther. 2014 Jan-Feb;21(1):56-66. doi: 10.1097/MJT.0b013e31822b5603.
9
Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease.甘油三酯及富含甘油三酯的脂蛋白在心血管疾病病因学途径中的作用
Am J Cardiol. 2016 Jul 1;118(1):138-45. doi: 10.1016/j.amjcard.2016.04.004. Epub 2016 Apr 20.
10
Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.海洋 ω-3 脂肪酸的最新进展：血脂异常的管理和当前 ω-3 治疗选择。
Atherosclerosis. 2013 Oct;230(2):381-9. doi: 10.1016/j.atherosclerosis.2013.07.041. Epub 2013 Jul 31.
引用本文的文献
1
Application of the Weibull Model to Statins for Triglyceride Management in Patients With Hyperlipidaemia.威布尔模型在高脂血症患者甘油三酯管理中应用于他汀类药物的研究
Pharmacol Res Perspect. 2025 Aug;13(4):e70159. doi: 10.1002/prp2.70159.
2
Machine learning-based high-benefit approach versus traditional high-risk approach in statin therapy: the Shizuoka Kokuho database study.他汀类药物治疗中基于机器学习的高获益方法与传统高风险方法的比较：静冈国保数据库研究
Sci Rep. 2025 Jul 29;15(1):27627. doi: 10.1038/s41598-025-11236-y.
3
The variations in health cost based on the traditional obesity parameters among patients with coronary artery diseases undergoing cardiac catheterization.经心脏导管检查的冠心病患者基于传统肥胖参数的健康费用变化。
BMC Health Serv Res. 2024 Sep 16;24(1):1071. doi: 10.1186/s12913-024-11486-y.
4
When Blood Is Thicker Than Water: A Case of Acute Pancreatitis Secondary to Familial Hypertriglyceridemia.血浓于水：一例家族性高甘油三酯血症继发急性胰腺炎
Cureus. 2024 Jan 2;16(1):e51511. doi: 10.7759/cureus.51511. eCollection 2024 Jan.
5
Metabolic Syndrome and Cardiometabolic Risk Factors in the Mixed Hypercholesterolemic Populations with Respect to Gender, Age, and Obesity in Asir, Saudi Arabia.沙特阿拉伯阿西尔地区混合性高胆固醇血症人群中，基于性别、年龄和肥胖情况的代谢综合征和心血管代谢危险因素。
Int J Environ Res Public Health. 2022 Nov 14;19(22):14985. doi: 10.3390/ijerph192214985.
本文引用的文献
1
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.依折麦布辛伐他汀对全因缺血事件的影响：来自 REDUCE-IT 研究。
J Am Coll Cardiol. 2019 Jun 11;73(22):2791-2802. doi: 10.1016/j.jacc.2019.02.032. Epub 2019 Mar 18.
2
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2019美国心脏病学会/美国心脏协会心血管疾病一级预防指南：美国心脏病学会/美国心脏协会临床实践指南工作组报告
Circulation. 2019 Sep 10;140(11):e596-e646. doi: 10.1161/CIR.0000000000000678. Epub 2019 Mar 17.
3
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2018年美国心脏协会/美国心脏病学会/美国心血管和肺康复协会/美国医师助理学会/美国心脏协会临床心脏病学分会/美国预防医学学会/美国糖尿病协会/美国老年医学会/美国药剂师协会/美国医学主任协会/美国国家脂质协会/美国初级保健医师学会血液胆固醇管理指南：美国心脏病学会/美国心脏协会临床实践指南工作组报告
J Am Coll Cardiol. 2019 Jun 25;73(24):e285-e350. doi: 10.1016/j.jacc.2018.11.003. Epub 2018 Nov 10.
4
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2018年美国心脏协会/美国心脏病学会/美国心血管和肺康复协会/美国医师助理学会/美国心脏协会/美国预防医学学会/美国糖尿病协会/美国老年医学会/美国药剂师协会/美国临床内分泌医师协会/美国国家脂质协会/美国初级保健医师学会血胆固醇管理指南：执行摘要：美国心脏病学会/美国心脏协会临床实践指南工作组报告
J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209. doi: 10.1016/j.jacc.2018.11.002. Epub 2018 Nov 10.
5
ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes.ASCEND：一项糖尿病心血管事件研究：随机试验中阿司匹林和ω-3 脂肪酸补充剂在 15480 名糖尿病患者中的特点。
Am Heart J. 2018 Apr;198:135-144. doi: 10.1016/j.ahj.2017.12.006. Epub 2017 Dec 24.
6
Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.ω-3 脂肪酸补充剂的使用与心血管疾病风险的关联：涉及 77917 人的 10 项试验的荟萃分析。
JAMA Cardiol. 2018 Mar 1;3(3):225-234. doi: 10.1001/jamacardio.2017.5205.
7
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.依折麦布联合他汀类药物治疗急性冠脉综合征。
N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.
8
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.男性和女性的 LDL 降低治疗的疗效和安全性：27 项随机试验中 174000 名参与者的个体数据汇总分析。
Lancet. 2015 Apr 11;385(9976):1397-405. doi: 10.1016/S0140-6736(14)61368-4. Epub 2015 Jan 9.
9
Effect of long-chain ω-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.长链 ω-3 脂肪酸和叶黄素+玉米黄质补充剂对心血管结局的影响：年龄相关性眼病研究 2（AREDS2）随机临床试验的结果。
JAMA Intern Med. 2014 May;174(5):763-71. doi: 10.1001/jamainternmed.2014.328.
10
Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study.低非空腹甘油三酯与全因死亡率降低：一项孟德尔随机化研究。
Clin Chem. 2014 May;60(5):737-46. doi: 10.1373/clinchem.2013.219881. Epub 2014 Jan 16.
Zotero 插件